With a one year PEG ratio of 0.2, Sol-Gel Technologies Ltd is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.26% of US stocks.
With a year-over-year growth in debt of -96.87%, Sol-Gel Technologies Ltd's debt growth rate surpasses merely 1.38% of about US stocks.
Revenue growth over the past 12 months for Sol-Gel Technologies Ltd comes in at 13,063.22%, a number that bests 99.86% of the US stocks we're tracking.
Stocks with similar financial metrics, market capitalization, and price volatility to Sol-Gel Technologies Ltd are LIFE, ZLAB, IMMU, CRSP, and CLSD.
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel
Sol-Gel Technologies, Ltd. (SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that it has entered into collaborative agreements with Perrigo Company plc (“Perrigo”) (NYSE; TASE: PRGO), for the development, manufacturing and commercialization of three new, generic product candidates. Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for these generic product candidates.
In this article we will check out the progression of hedge fund sentiment towards Sol-Gel Technologies Ltd. (NASDAQ:SLGL) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]